Scientific Sessions 2025  /  Annual Lipid Update 2025  /  Will CETP inhibition PREVAIL in CVD prevention?
Logo

American Heart Association

  32
  0

Final ID:

Will CETP inhibition PREVAIL in CVD prevention?

  • Nicholls, Stephen  ( Victorian Heart Hospital , Clayton , Victoria , Australia )
    • Author Disclosures:
    Stephen Nicholls: DO have relevant financial relationships ; Researcher:AstraZeneca, NewAmsterdam Pharma, Amgen, Anthera, Cyclarity, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron, and LipoScience:Active (exists now) ; Consultant:Abcentra, AstraZeneca, Amarin, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim, Daiichi Sankyo, Scribe Therapeutics, Silence Therapeutics, CSL Seqirus and Vaxxinity:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Annual Lipid Update 2025

Sunday, 11/09/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
What LDL-C (or ApoB) level should we be targeting? And how ASCVD history inform LDL-C targets?

Khera Amit, Joshi Parag

Targeting PCSK9 to lower LDL-C and CVD risk – A growing array of options

Bohula Erin, Odonoghue Michelle

More abstracts from these authors:
Will dual GIP and GLP1 receptor agonism SURPASS existing GLP1RAs?

Sattar Naveed, Nicholls Stephen

CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3

Nicholls Stephen

You have to be authorized to contact abstract author. Please, Login
Not Available